{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+Part+B", "query": { "intervention": "Placebo Part B" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 724, "total_pages": 73, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+Part+B&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-09T20:17:07.914Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02365571", "title": "A Study of LY3154207 in Healthy Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Participants" ], "interventions": [ { "name": "LY3154207", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Itraconazole", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 64, "start_date": "2015-02", "completion_date": "2015-05", "has_results": false, "last_update_posted_date": "2015-06-11", "last_synced_at": "2026-09-09T20:17:07.914Z", "location_count": 1, "location_summary": "Salt Lake City, Utah", "locations": [ { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT02365571" }, { "nct_id": "NCT07525544", "title": "A Study to Investigate the Safety and PK of VH4770359 in Healthy Participants", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "VH4770359", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Midazolam", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ViiV Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 214, "start_date": "2026-05-14", "completion_date": "2027-05-05", "has_results": false, "last_update_posted_date": "2026-07-13", "last_synced_at": "2026-09-09T20:17:07.914Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT07525544" }, { "nct_id": "NCT03467932", "title": "A Study to Evaluate the Efficacy and Safety of ORMD-0801 (Oral Insulin) in Patients With Type 2 Diabetes Mellitus", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "T2DM (Type 2 Diabetes Mellitus)" ], "interventions": [ { "name": "Cohort A: ORMD-0801", "type": "DRUG" }, { "name": "Placebo oral capsule", "type": "DRUG" }, { "name": "Cohort B: ORMD-0801", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Oramed, Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 373, "start_date": "2018-05-29", "completion_date": "2020-02-18", "has_results": true, "last_update_posted_date": "2022-11-08", "last_synced_at": "2026-09-09T20:17:07.914Z", "location_count": 1, "location_summary": "Flint, Michigan", "locations": [ { "city": "Flint", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT03467932" }, { "nct_id": "NCT05831111", "title": "A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Epstein-Barr Virus Infection" ], "interventions": [ { "name": "mRNA-1195.1", "type": "BIOLOGICAL" }, { "name": "mRNA-1195.2", "type": "BIOLOGICAL" }, { "name": "mRNA-1189", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "BIOLOGICAL" }, { "name": "mRNA-1195", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "ModernaTX, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 482, "start_date": "2023-04-05", "completion_date": "2026-10-13", "has_results": false, "last_update_posted_date": "2026-08-11", "last_synced_at": "2026-09-09T20:17:07.914Z", "location_count": 34, "location_summary": "Anniston, Alabama • Tucson, Arizona • Huntington Beach, California + 30 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Huntington Beach", "state": "California" }, { "city": "Longmont", "state": "Colorado" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05831111" }, { "nct_id": "NCT05516498", "title": "Zibotentan and Dapagliflozin Combination, EvAluated in Liver Cirrhosis (ZEAL Study)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Liver Cirrhosis" ], "interventions": [ { "name": "Part A: Placebo (matching zibotentan capsule & matching dapagliflozin tablet)", "type": "DRUG" }, { "name": "Part A: zibotentan (dose B) + dapagliflozin", "type": "DRUG" }, { "name": "Part B: Placebo (matching zibotentan capsule & matching dapagliflozin tablet)", "type": "DRUG" }, { "name": "Part B: placebo (matching zibotentan capsule) + dapagliflozin", "type": "DRUG" }, { "name": "Part B: zibotentan (dose A) + dapagliflozin", "type": "DRUG" }, { "name": "Part B: zibotentan (dose B) + dapagliflozin", "type": "DRUG" }, { "name": "Part B: zibotentan (dose C) + dapagliflozin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 205, "start_date": "2022-10-31", "completion_date": "2025-07-17", "has_results": false, "last_update_posted_date": "2025-08-15", "last_synced_at": "2026-09-09T20:17:07.914Z", "location_count": 11, "location_summary": "Birmingham, Alabama • Pasadena, California • San Francisco, California + 8 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Pasadena", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "West Hollywood", "state": "California" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT05516498" }, { "nct_id": "NCT02465437", "title": "Safety, Tolerability, Efficacy, and Pharmacokinetics of JBT-101 in Systemic Sclerosis", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Diffuse Cutaneous Systemic Sclerosis" ], "interventions": [ { "name": "JBT-101", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Part B Open-Label Extension", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Corbus Pharmaceuticals Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 42, "start_date": "2015-08", "completion_date": "2020-12-11", "has_results": true, "last_update_posted_date": "2021-04-21", "last_synced_at": "2026-09-09T20:17:07.914Z", "location_count": 9, "location_summary": "Los Angeles, California • Palo Alto, California • Baltimore, Maryland + 6 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New Brunswick", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT02465437" }, { "nct_id": "NCT06593457", "title": "A Food-Effect, Drug-Drug Interaction, and Pharmacokinetics Study of NX-5948 in Healthy Adult Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteers" ], "interventions": [ { "name": "IP", "type": "DRUG" }, { "name": "Matching Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Nurix Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "MALE", "summary": "18 Years to 55 Years · Male only" }, "enrollment_count": 32, "start_date": "2024-08-20", "completion_date": "2024-11-14", "has_results": false, "last_update_posted_date": "2025-03-14", "last_synced_at": "2026-09-09T20:17:07.914Z", "location_count": 1, "location_summary": "Lincoln, Nebraska", "locations": [ { "city": "Lincoln", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT06593457" }, { "nct_id": "NCT02344303", "title": "Study of the Effects of TRV130, at Therapeutic and Supra Therapeutic Doses, on QTc Intervals", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "TRV130", "type": "DRUG" }, { "name": "Moxifloxacin", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Trevena Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "ALL", "summary": "18 Years to 45 Years" }, "enrollment_count": 63, "start_date": "2014-12", "completion_date": "2015-10", "has_results": false, "last_update_posted_date": "2017-05-12", "last_synced_at": "2026-09-09T20:17:07.914Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02344303" }, { "nct_id": "NCT03981822", "title": "A Placebo-Controlled Study Using VP-102 in the Treatment of External Genital Warts", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Condylomata Acuminata", "Papillomavirus Infections", "Skin Diseases, Viral", "Skin Diseases, Infectious", "Skin Diseases", "Sexually Transmitted Diseases, Viral", "Sexually Transmitted Diseases", "Warts" ], "interventions": [ { "name": "VP-102 and applicator", "type": "COMBINATION_PRODUCT" }, { "name": "Placebo", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "COMBINATION_PRODUCT" ], "sponsor": "Verrica Pharmaceuticals Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 105, "start_date": "2019-06-25", "completion_date": "2020-07-08", "has_results": true, "last_update_posted_date": "2024-11-27", "last_synced_at": "2026-09-09T20:17:07.914Z", "location_count": 4, "location_summary": "Plainfield, Indiana • Baton Rouge, Louisiana • Clarkston, Michigan + 1 more", "locations": [ { "city": "Plainfield", "state": "Indiana" }, { "city": "Baton Rouge", "state": "Louisiana" }, { "city": "Clarkston", "state": "Michigan" }, { "city": "Tulsa", "state": "Oklahoma" } ], "official_url": "https://clinicaltrials.gov/study/NCT03981822" }, { "nct_id": "NCT03627494", "title": "First Time in Human (FTIH) Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Single and Repeat Doses of GSK3439171A in Healthy Subjects and to Assess Food Effect", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Muscular Dystrophies" ], "interventions": [ { "name": "GSK3439171A", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "MALE", "summary": "18 Years to 65 Years · Male only" }, "enrollment_count": 66, "start_date": "2018-08-30", "completion_date": "2019-08-26", "has_results": true, "last_update_posted_date": "2020-07-10", "last_synced_at": "2026-09-09T20:17:07.914Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03627494" } ] }